TrialNature medicine2023

Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results.

Martin Gutierrez et al.PubMed ↗Publisher ↗

No numbers read from the abstract.